GCG and type 2 diabetes mellitus: Although it has been suggested in recent meta-analyses that Asians may have greater cardiovascular benefit than White people with type 2 diabetes from long-acting GLP-1 RA therapy [3, 5], the present data do not support race-specific differences in key CVD risk factors as an underlying mechanism.